Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study

Table 1 Pretreatment clinical characteristics including baseline body compositions of the study subjects

Variables	N = 30
Age, years	66.5 [46–87]
Sex, M/F	17 (57%) /13 (43%)
Etiology of liver cirrhosis
HCV/ Alcoholism /NASH /Others	11 (37%)/10 (33%) /4 (13%)/15 (17%)
Child-Pugh-Turcotte class, B/C	15/15
MELD score	13.5 [8–29]
MELDNa score	18.5 [8–32]
MAP, mmHg	82 [65–106]
Baseline diuretics
Furosemide, mg/day	22.5 [0–160]
Spironolactone, mg/day	37.5 [0–100]
Pre-treatment biochemical studies
Total bilirubin, mg/dL	2.0 [0.3–12.6]
PT-INR	1.23 [0.96–2.42]
Serum sodium, mmol/L	133.8 [122.3–142.8]
Albumin, g/dL	2.4 [1.6–3.9]
BUN, mg/dL	20.8 [5.9–47.1]
Serum creatinine, mg/dL	1.00 [0.48–2.49]
ALT, IU/L	25 [7–75]
GGTP, IU/L	70 [11–359]
AVP, pg/mL	1.8 [0.8–6.3]
Aldosterone, pg/mL	208 [18–1200]
Serum osmolality, mOsm/kg. H₂O	285 [250–295]
Urine osmolality, mOsm/kg. H₂O	448 [59–838]
Body Compositions; baseline
BMI, kg/m²	23.2 [16.7–32.7]
Skeletal muscle index, kg/m²	9.1 [7.1–16.0]
TBW_BIA-c ^a, L/m²	20.4 [17.9–24.0]
ECW_BIA-c ^a, L/m²	8.3 [6.7–10.1]
ICW_BIA-c ^a, L/m²	12.0 [9.6–14.0]
ECW_BIA/TBW_BIA	0.40 [0.37–0.46]

Data are shown as median with the range within brackets, or numbers
Abbreviations: M Male, F Female, HCV Hepatitis virus C, MELD Model for end-stage liver disease, MAP Mean arterial blood pressure, PT-INR Prothrombin time- international ratio, BUN Blood urea nitrogen, ALT Alanine transaminase, GGTP γ- glutamyl transpeptidase, AVP Arginine vasopressin, BMI Body mass index, TBW Total body water, BIA Bioimpedance analysis, ECW Extracellular water, ICW Intracellular water
*, P < 0.05; **, P < 0.01; ***, P < 0.0001
^aTBW_BIA-c, ECW_BIA-c, ICW_BIA-c were normalized by body surface area (m²)

ISSN: 1471-230X